Your browser doesn't support javascript.
loading
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia / ¿Por qué elegir ciclosporina A como primera línea terapéutica para la neumonía causada por COVID-19?
Sanchez-Pernaute, Olga; Romero-Bueno, Fredeswinda I; Selva-O’Callaghan, Albert.
Affiliation
  • Sanchez-Pernaute, Olga; Jiménez Díaz Foundation University Hospital. Rheumatology Division. Health Research Institute, Universidad Autónoma de Madrid. Madrid. Spain
  • Romero-Bueno, Fredeswinda I; Jiménez Díaz Foundation University Hospital. Rheumatology Division. Health Research Institute, Universidad Autónoma de Madrid. Madrid. Spain
  • Selva-O’Callaghan, Albert; Hospital Universitari Val d’Hebron. Department of Internal Medicine. Universitat Autonoma de Barcelona. Barcelona. Spain
Reumatol. clín. (Barc.) ; 17(9): 555-557, Nov. 2021. ilus
Article in English | IBECS | ID: ibc-213366
Responsible library: ES1.1
Localization: ES15.1 - BNCS
Subject(s)
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Antiviral Agents / Pneumonia / Cyclosporine / Coronavirus Infections / Severe acute respiratory syndrome-related coronavirus / Pandemics / Immunosuppressive Agents Limits: Humans Language: English Journal: Reumatol. clín. (Barc.) Year: 2021 Document type: Article Institution/Affiliation country: Hospital Universitari Val d’Hebron/Spain / Jiménez Díaz Foundation University Hospital/Spain
Fulltext
Add to My VHL
Print
XML
Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Antiviral Agents / Pneumonia / Cyclosporine / Coronavirus Infections / Severe acute respiratory syndrome-related coronavirus / Pandemics / Immunosuppressive Agents Limits: Humans Language: English Journal: Reumatol. clín. (Barc.) Year: 2021 Document type: Article Institution/Affiliation country: Hospital Universitari Val d’Hebron/Spain / Jiménez Díaz Foundation University Hospital/Spain